US$ 21.01
do not combine dpp-4 inhibitor with glp-1 receptor agonist guideline Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology Neuroprotection by dipeptidyl-peptidase-4 inhibitors and
Description
Its generally reserved for patients meeting strict criteria (e.g

Rather, it focused on specifically determining the cardiovascular superiority of dulaglutide relative to cardiovascular endpoints

doi: 10.1177/1535370215576313 [DOI] [PMC free article] [PubMed] [Google Scholar] 113.Imamura K, Hishikawa N, Sawada M, et al

Cardiovasc Drugs Ther (2013) 27(2):1338

doi: 10.1136/dtb.2009.10.0046

But it is alarming if you are not expecting it
